Roth Capital lowered its price target on Dendreon Corp. (Nasdaq: DNDN) from $12 to $6.70 saying that the biotechnology firm's prostate cancer treatment Provenge may lose market share. The stock price fell 85 cents to $5.91.
Dendreon's Price Target Lowered
June 04, 2012 at 14:30 PM EDT